OCULAR THERAPEUTIX, INC.

(OCUL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

01/04/2022 | 08:03am EDT

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.

In addition to the presentation, the management team will host virtual investor meetings. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.

A webcast of the pre-recorded presentation will be made available the morning of the conference starting at 7:00 AM ET on Monday, January 10th, and can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will be available for replay for 90 days.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix has completed Phase 2 clinical trials for OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.


© Business Wire 2022
All news about OCULAR THERAPEUTIX, INC.
05/11Berenberg Bank Cuts Price Target on Ocular Therapeutix to $21 From $23, Maintains Buy R..
MT
05/10Ocular therapeutix reports first quarter 2022 financial results and business update
AQ
05/10HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $14, Reiterates Bu..
MT
05/10Piper Sandler Adjusts Price Target on Ocular Therapeutix to $16 From $20, Reiterates Ov..
MT
05/09OCULAR THERAPEUTIX : Q1 Earnings Snapshot
AQ
05/09TRANSCRIPT : Ocular Therapeutix, Inc., Q1 2022 Earnings Call, May 09, 2022
CI
05/09OCULAR THERAPEUTIX, INC Management's Discussion and Analysis of Financial Condition an..
AQ
05/09Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $13.2M, vs. Street Est of $13..
MT
05/09Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/09Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Upd..
BU
More news
Analyst Recommendations on OCULAR THERAPEUTIX, INC.
More recommendations
Financials (USD)
Sales 2022 60,4 M - -
Net income 2022 -71,2 M - -
Net cash 2022 48,0 M - -
P/E ratio 2022 -3,80x
Yield 2022 -
Capitalization 257 M 257 M -
EV / Sales 2022 3,46x
EV / Sales 2023 2,43x
Nbr of Employees 228
Free-Float 99,4%
Chart OCULAR THERAPEUTIX, INC.
Duration : Period :
Ocular Therapeutix, Inc. Technical Analysis Chart | OCUL | US67576A1007 | MarketScreener
Technical analysis trends OCULAR THERAPEUTIX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,35 $
Average target price 17,71 $
Spread / Average Target 429%
EPS Revisions
Managers and Directors
Antony Mattessich President, Chief Executive Officer & Director
Donald Notman Chief Financial Officer
Charles M. Warden Chairman
Peter Jarrett Chief Scientific Officer
Michael H. Goldstein Chief Medical Officer & Ophthalmology President
Sector and Competitors
1st jan.Capi. (M$)
OCULAR THERAPEUTIX, INC.-51.94%257
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707